BSE Live
Mar 13, 16:01Prev. Close
12.38
Open Price
12.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:58Prev. Close
12.40
Open Price
12.40
Bid Price (Qty.)
12.06 (45)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Syncom Formulations (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 17 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 65.51 | 33.98 | 26.56 | 26.15 | 15.88 | |
| Net CashFlow From Operating Activities | 23.44 | -5.96 | 10.53 | 16.33 | 13.84 | |
| Net Cash Used In Investing Activities | -18.20 | 83.02 | -44.95 | -27.07 | -17.68 | |
| Net Cash Used From Financing Activities | -67.90 | -14.56 | 35.00 | 8.29 | 4.67 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -62.67 | 62.50 | 0.58 | -2.45 | 0.83 | |
| Cash And Cash Equivalents Begin of Year | 63.38 | 0.88 | 0.30 | 2.75 | 5.69 | |
| Cash And Cash Equivalents End Of Year | 0.71 | 63.38 | 0.88 | 0.30 | 6.52 |
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth